| NCT ID | NCT02936791 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Polycystic Kidney Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2016-04 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2016-04 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested.
Eligibility Criteria
Inclusion Criteria: * Inclusion for early stage autosomal dominant polycystic kidney disease (ADPKD): * Family history of PKD * All races and ethnic groups * Glomerular filtration rate (GFR) \>80 ml/min per 1.73 m2 * Inclusion for Healthy Volunteers: * Male or female with no family history of kidney disease * All races and ethnic groups * Normal GFR Exclusion Criteria: * Non-insulin or insulin-dependent diabetes mellitus * Systemic illness (i.e.systemic lupus erythematosus, vasculitis) * Unable to provide written informed consent * Unavailable for magnetic resonance imaging (MRI) and blood/urine collection
Contact & Investigator
Alan SL Yu, MD
PRINCIPAL INVESTIGATOR
University of Kansas Medical Center
Frequently Asked Questions
Who can join the NCT02936791 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, up to 35 Years, studying Polycystic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02936791 currently recruiting?
Yes, NCT02936791 is actively recruiting participants. Contact the research team at ccreed@kumc.edu for enrollment information.
Where is the NCT02936791 trial being conducted?
This trial is being conducted at Chicago, United States, Kansas City, United States, Kansas City, United States.
Who is sponsoring the NCT02936791 clinical trial?
NCT02936791 is sponsored by University of Kansas Medical Center. The principal investigator is Alan SL Yu, MD at University of Kansas Medical Center. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.